Cовременные представления об идеальной комбинации антигипертензивных препаратов для профилактики инсульта
Аннотация
Об авторах
О. Д. ОстроумоваРоссия
В. М. Фомина
Россия
Т. Ф. Гусева
Россия
Список литературы
1. Смертность населения Российской Федерации, 1998 г. (статистические материалы). М.: Минздрав РФ, 2006.
2. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журн. неврологии и психиатрии. 2007; 8: 4–10.
3. Диагностика и лечение артериальной гипертензии. Системные гипертензии. 2010; 3: 5–26.
4. Lewington S, Clarke R, Qizilbash N et al. Prospective Studies Collaboration. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13.
5. Staessen J.A, Wang J-G, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–76.
6. Reboldi G, Angeli F, Cavallini C et al. Comparison between angiotensin - converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta - analysis. J Hypertens 2008; 26 (7): 1282–9.
7. Dahlöf B, Devereux R.B, Kjeldsen S.E et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet 2002; 359: 995–1003.
8. Dahlöf B, Devereux R.B, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study. Am J Hypertens 1997; 10: 705–13.
9. Verdecchia P Porcellati C, Reboldi G et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039–44.
10. Верещагин Н.В. Гетерогенность инсульта в клинической практике. Атмосфера. Нервные болезни. 2004; 1: 19–20.
11. Dempsey R.J, Diana A.L, Moore R.W. Thickness of carotid artery atherosclerotic plaque and ischemic risk. Neurosurgery 1990; 27 (3): 343–8.
12. Olsen M.H, Wachtell K, Neland K et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177–83.
13. Sonoda M, Aoyagi T, Takenaka K et al. A One-Year Study of the Antiatherosclerotic Effect of the Angiotensin-II Receptor Blocker Losartan in Hypertensive Patients (A Comparison With Angiotensin-Converting Enzyme Inhibitors). Int Heart J 2008; 49 (1): 95–103.
14. Strawn W.B, Chappell M.C, Dean R.H et al. Inhibition of early atherogenesis by losartan in monkeys with diet - induced hypercholesterolemia. Circulation 2000; 101: 1586–93.
15. Schiffrin E.L, Park J.B, Intengan H.D et al. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653–9.
16. Prasad A, Tupas-Habib T, Schenke W.H et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–54.
17. Cheetham C, Collis J, O’Driscoll G et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non - insulin - dependent diabetes. J Am Coll Cardiol 2000; 36 (5): 1461–6.
18. Hornig B, Landmesser U, Kohler C et al. Comparative effect of ACE inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799–805.
19. Guerra-Cuesta J.I, Montón M, Rodriguez-Feo J.A et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447–52.
20. Erdem Y, Usalan C, Haznedaroğlu I.C et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999; 11: 1071–6.
21. Levy P.J, Yunis C, Owen J et al. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000; 86: 1188–92.
22. Fogari R, Zoppi A, Malamani G et al. Effects of four angiotensin II-receptor antagonists on fibrinolysis in postmenopausal women with hypertension. Curr Ther Res Clin Exp 2001; 62: 68–78.
23. Krämer C, Sunkomat J, Witte J et al. Angiotensin II receptor - independent antiinflammatory and antiaggregatory properties of losartan: Role of the active metabolite EXP3179. Circ Res 2002; 90: 770–6.
24. Wolf P.A, Abbott R.D, Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8.
25. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new - onset atrial fibrillation and subsequent stroke compared to atenolol: The LIFE Study. J Am Coll Cardiol 2005; 45: 712–9.
26. Devereux R.B, Bella J, Boman K et al. Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE Study. Blood Press 2001; 10: 74–82.
27. Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with atrial fibrillation: The LIFE study. J Am Coll Cardiol 2005; 45: 705–11.
28. Olsen M.H, Wachtell K, Bella J.N et al. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a Losartan Intervention For Endpoint reduction in hypertension (LIFE) substudy. Am J Hypertens 2005; 18: 1430–6.
29. Ibsen H, Wachtell K, Olsen M.H et al., for the LIFE Substudy. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805–11.
30. Kobel F, Gregorova I, Sonka J. Hyperuricaemia in hypertension. Lancet 1965; 1: 519–20.
31. Kinsey D, Walther R, Sise H.S et al. Incidence of hyperuricaemia in 400 hypertensive patients. Circulation 1961; 24: 972–3.
32. France L.V, Pahor M, Di Bari M et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149–54.
33. Hoieggen A, Alderman M.H, Kjeldsen S.E et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041–9.
34. Sweet C.S, Bradstreet D.C, Berman R.S et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7 (12): 1035–40.
35. Burnier M, Hagmann M, Nussberger I et al. Short - term and sustained renal effects of angiotensin II receptor blockade in healthy subjects. Hypertension 1995; 25 (4p 1): 602–9.
36. Shahinfar S, Simpson R, Carides A et al. Safety of losartan in hypertensive patients with asymptomatic hyperuricemia. JASN 1997; 8: 322.
37. Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on progression of atherosclerosis and the occurrence of clinical events. PREVENT investigators. Circulation 2000; 102 (13): 1503–10.
38. Webb A.J.S, Fischer U, Mehta Z, Rothwell P.M. Effects of antihypertensive - drug class on interindividual variation in BP and risk of stroke: a systematic review and meta - analysis. Lancet 2010; 375: 906–15.
39. Rothwell P.M, Webb A.J.S. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke 2011; 42: 2860–5.
40. Rothwell P.M, Howard S.C, Dolan E et al. Prognostic significance of visit - to - visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010; 375: 895–905.
Рецензия
Для цитирования:
Остроумова О.Д., Фомина В.М., Гусева Т.Ф. Cовременные представления об идеальной комбинации антигипертензивных препаратов для профилактики инсульта. Системные гипертензии. 2013;10(3):71-76.
Послать статью по эл. почте 